The investigational drug avacopan, an oral inhibitor of complement activation, showed meaningful clinical activity in the treatment of C3 glomerulopathy, indicates the largest study ever done in this rare kidney disease. In a group of 52 participants, there was a “clear trend” in favor of those treated with active therapy, with a mean reduction in […]